Osr Holdings Inc (OSRH)

$0.57 +0.01 (1.95%)
Market Cap 14.99M
Revenue (ttm) 0.00
Net Income (ttm) -2.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.03
Volume 685,400
Avg Vol 5,800,278
Day's Range N/A - N/A
Shares Out 25.67M
Stochastic %K 8%
Beta 1.42
Analysts Strong Buy
Price Target N/A

Company Profile

OSR Holdings, Inc., a healthcare holding company, develops a portfolio of therapies and healthcare solutions in the United States, Switzerland, and South Korea. The company develops immunotherapy products, including VXM01, an immuno-oncology candidate for glioblastoma that is in phase 2 clinical trial, as well as preclinical stage products, such as VXM04 to treat mesothelin; VXM06 for the treatment of Wilms Tumor Protein (WT1); VXM08 for Carcinoembryonic antigen (CEA); and VXM10 for PD-L1. It is...

Industry: Biotechnology
Sector: Healthcare
Phone: 425 635 7700
Address:
10900 NE 4th Street, Suite 2300, Bellevue, United States
KeepItRealistic
KeepItRealistic Feb. 4 at 1:54 AM
$OSRH 🤔 👇
0 · Reply
Spiderman1979
Spiderman1979 Feb. 4 at 1:52 AM
$OSRH anyone else see that jump?
1 · Reply
Spiderman1979
Spiderman1979 Feb. 4 at 1:51 AM
$OSRH stop teasing me baby! Lol
0 · Reply
KeepItRealistic
KeepItRealistic Feb. 4 at 1:35 AM
$OSRH potential of being worth multi billion dollars which explains why BCM Europe is willing to invest a staggering $815 million 👇 And peeps are selling their shares for nothing 🤷🏻‍♂️
0 · Reply
Bearbull_Baggins
Bearbull_Baggins Feb. 4 at 12:28 AM
$OSRH Just one spoke of this hub we call OSR Holdings
1 · Reply
KeepItRealistic
KeepItRealistic Feb. 3 at 7:25 PM
$OSRH I can hold a couple months for $10+ No brainer 👇
2 · Reply
KeepItRealistic
KeepItRealistic Feb. 3 at 6:48 PM
$OSRH news expected 👇 “As a result of this improved regulatory visibility, Woori IO has recently begun receiving proactive inbound interest from global device distributors, including potential partners prepared to act as importers and local agencies across key international markets. The company aims to announce formal distribution engagements in due course.”
0 · Reply
GemstoneTrades
GemstoneTrades Feb. 3 at 6:28 PM
$OSRH Based on the heavy concentration of news we've seen in the last few weeks, there is a clear "news cycle" pattern forming. The next piece of news will likely drop within the next 7 to 14 days (roughly between February 10th and February 17th, 2026). Here is why that specific window is the most probable: If you look at their recent PR history, they have been releasing a major update roughly every 5 to 10 days: Jan 22: FDA Clarification news. Jan 27: Woori IO Acquisition closing. Feb 2: CEO Statement to Shareholders. Next Window: Mid-February.
0 · Reply
TySpy
TySpy Feb. 3 at 3:31 PM
$OSRH Q elevator music while we wait 🤣
1 · Reply
KeepItRealistic
KeepItRealistic Feb. 3 at 2:47 PM
$OSRH RS fears debunked 👇 See you over $1
0 · Reply
Latest News on OSRH
CEO Statement to Shareholders

Feb 2, 2026, 9:50 AM EST - 1 day ago

CEO Statement to Shareholders

OSR Holdings Completes Woori IO Acquisition, Secures Long-Term Shareholder Alignment, and Reviews Strategic Combination of Medical Device Subsidiaries

Jan 27, 2026, 8:30 AM EST - 7 days ago

OSR Holdings Completes Woori IO Acquisition, Secures Long-Term Shareholder Alignment, and Reviews Strategic Combination of Medical Device Subsidiaries

Woori IO, an OSR Company, Highlights FDA Clarification on Non-Medical Wearables as a Catalyst for Accelerated Commercial Launch

Jan 22, 2026, 9:55 AM EST - 12 days ago

Woori IO, an OSR Company, Highlights FDA Clarification on Non-Medical Wearables as a Catalyst for Accelerated Commercial Launch

Vaximm Appoints Sébastien Wieckowski, PhD, as Chief Scientific Officer to Advance Next-Generation Oral Immunotherapy Platform

Jan 16, 2026, 9:20 AM EST - 18 days ago

Vaximm Appoints Sébastien Wieckowski, PhD, as Chief Scientific Officer to Advance Next-Generation Oral Immunotherapy Platform

Vaximm, an OSR Company, Receives Binding Term Sheet from BCM Europe for Global Exclusive License of VXM01 with $30M Upfront and Up to $815M in Milestones

Jan 12, 2026, 8:05 AM EST - 22 days ago

Vaximm, an OSR Company, Receives Binding Term Sheet from BCM Europe for Global Exclusive License of VXM01 with $30M Upfront and Up to $815M in Milestones

Woori IO Shareholders Approve Share Exchange to Become Wholly-Owned Subsidiary of OSR Holdings

Dec 19, 2025, 11:50 AM EST - 6 weeks ago

Woori IO Shareholders Approve Share Exchange to Become Wholly-Owned Subsidiary of OSR Holdings

Emerging Growth Research Issues Flash Report on OSR Holdings, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target Following Major Licensing Agreement

Dec 4, 2025, 3:19 PM EST - 2 months ago

Emerging Growth Research Issues Flash Report on OSR Holdings, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target Following Major Licensing Agreement

Vaximm AG, an OSR Company, Updates Term Sheet with BCM Europe to Shorten Exclusivity Period to Three Months

Dec 2, 2025, 9:53 AM EST - 2 months ago

Vaximm AG, an OSR Company, Updates Term Sheet with BCM Europe to Shorten Exclusivity Period to Three Months

OSR Holdings to Present at the Emerging Growth Conference on December 10, 2025

Dec 1, 2025, 3:01 PM EST - 2 months ago

OSR Holdings to Present at the Emerging Growth Conference on December 10, 2025

Vaximm AG, an OSR Company, Enters Term Sheet With BCM Europe for Potential VXM01 License with $20M Upfront and Up to $815M in Milestones

Nov 21, 2025, 9:20 AM EST - 2 months ago

Vaximm AG, an OSR Company, Enters Term Sheet With BCM Europe for Potential VXM01 License with $20M Upfront and Up to $815M in Milestones

OSR Holdings Appoints Scientific Co-Founder Dr. Andreas Niethammer as Chief Executive Officer of Vaximm AG to Lead Next Phase of Immuno-Oncology Expansion

Nov 14, 2025, 11:10 AM EST - 2 months ago

OSR Holdings Appoints Scientific Co-Founder Dr. Andreas Niethammer as Chief Executive Officer of Vaximm AG to Lead Next Phase of Immuno-Oncology Expansion

OSR Holdings Announces Woori IO's Noninvasive Glucose Monitor Demonstrates High Accuracy and Precision in Company-Sponsored Pilot Study

Nov 6, 2025, 8:30 AM EST - 3 months ago

OSR Holdings Announces Woori IO's Noninvasive Glucose Monitor Demonstrates High Accuracy and Precision in Company-Sponsored Pilot Study

Emerging Growth Research Initiates Coverage on OSR Holdings, Inc. with a Buy-Emerging Rating and $10.00 Price Target

Oct 20, 2025, 11:39 AM EDT - 3 months ago

Emerging Growth Research Initiates Coverage on OSR Holdings, Inc. with a Buy-Emerging Rating and $10.00 Price Target

OSR Holdings Signs Definitive Agreement to Acquire Woori IO, a Pioneer in Noninvasive Glucose Monitoring with Potential to Transform Diabetes Care

Oct 14, 2025, 8:30 AM EDT - 4 months ago

OSR Holdings Signs Definitive Agreement to Acquire Woori IO, a Pioneer in Noninvasive Glucose Monitoring with Potential to Transform Diabetes Care

OSR Holdings Receives Nasdaq Minimum Bid Price Deficiency Notice; Company Highlights Unusual Trading Activity

Sep 9, 2025, 5:30 PM EDT - 5 months ago

OSR Holdings Receives Nasdaq Minimum Bid Price Deficiency Notice; Company Highlights Unusual Trading Activity

OSR Holdings to Host Virtual Investor Event Providing Key Corporate Updates and Strategic Direction on August 6, 2025

Aug 1, 2025, 1:29 PM EDT - 6 months ago

OSR Holdings to Host Virtual Investor Event Providing Key Corporate Updates and Strategic Direction on August 6, 2025

OSR Holdings Provides Transparency Update on Equity Financing Instruments

Jul 31, 2025, 12:45 PM EDT - 6 months ago

OSR Holdings Provides Transparency Update on Equity Financing Instruments

OSR Holdings Provides Strategic Update on Woori IO Term Sheet and Share Exchange Structure

Jul 30, 2025, 4:10 PM EDT - 6 months ago

OSR Holdings Provides Strategic Update on Woori IO Term Sheet and Share Exchange Structure

OSR Holdings Enters into Term Sheet to Acquire Woori IO, a Pioneer in Noninvasive Glucose Monitoring Technology

Jul 24, 2025, 7:30 AM EDT - 6 months ago

OSR Holdings Enters into Term Sheet to Acquire Woori IO, a Pioneer in Noninvasive Glucose Monitoring Technology

OSR Holdings Appoints Dr. Andreas Niethammer as Chief Medical Officer of Vaximm AG, an OSR Company

Jul 15, 2025, 7:30 AM EDT - 7 months ago

OSR Holdings Appoints Dr. Andreas Niethammer as Chief Medical Officer of Vaximm AG, an OSR Company

OSR Holdings Announces Strategic Roadmap for Tokenization Under Reg D Framework in Partnership with BCM Europe AG

Jul 9, 2025, 7:58 AM EDT - 7 months ago

OSR Holdings Announces Strategic Roadmap for Tokenization Under Reg D Framework in Partnership with BCM Europe AG

OSR Holdings, BCM Europe, and Taekwondo Cooperative Announce Strategic MOU to Launch Blockchain-Based OSRH Token

May 22, 2025, 7:36 AM EDT - 9 months ago

OSR Holdings, BCM Europe, and Taekwondo Cooperative Announce Strategic MOU to Launch Blockchain-Based OSRH Token

Darnatein to Present at 14th International BMP Conference Highlighting Advances in Regenerative Biologics

May 2, 2025, 7:30 AM EDT - 9 months ago

Darnatein to Present at 14th International BMP Conference Highlighting Advances in Regenerative Biologics

Darnatein, an OSR Company, Broadens Intellectual Property Protection for Innovative Osteoarthritis Treatment Technology

Apr 9, 2025, 7:54 AM EDT - 10 months ago

Darnatein, an OSR Company, Broadens Intellectual Property Protection for Innovative Osteoarthritis Treatment Technology

OSR Holdings, Inc. (NASDAQ: OSRH) Enters Into $80 Million Common Stock Purchase Agreement With White Lion GBM Innovation Fund, With An Eye Towards Leveraging Innovate GBM's Non-Profit Ecosystem to Accelerate Glioblastoma Therapies

Apr 3, 2025, 7:30 AM EDT - 10 months ago

OSR Holdings, Inc. (NASDAQ: OSRH) Enters Into $80 Million Common Stock Purchase Agreement With White Lion GBM Innovation Fund, With An Eye Towards Leveraging Innovate GBM's Non-Profit Ecosystem to Accelerate Glioblastoma Therapies

Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in Glioblastoma

Mar 26, 2025, 7:16 AM EDT - 11 months ago

Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in Glioblastoma

OSR Holdings Appoints Dr. Constance Höfer as Chief Scientific Officer

Mar 25, 2025, 7:00 AM EDT - 11 months ago

OSR Holdings Appoints Dr. Constance Höfer as Chief Scientific Officer

OSR Holdings, Inc. and OSR Holdings Co., Ltd. Announce Completion of Business Combination

Feb 14, 2025, 6:10 PM EST - 1 year ago

OSR Holdings, Inc. and OSR Holdings Co., Ltd. Announce Completion of Business Combination

KeepItRealistic
KeepItRealistic Feb. 4 at 1:54 AM
$OSRH 🤔 👇
0 · Reply
Spiderman1979
Spiderman1979 Feb. 4 at 1:52 AM
$OSRH anyone else see that jump?
1 · Reply
Spiderman1979
Spiderman1979 Feb. 4 at 1:51 AM
$OSRH stop teasing me baby! Lol
0 · Reply
KeepItRealistic
KeepItRealistic Feb. 4 at 1:35 AM
$OSRH potential of being worth multi billion dollars which explains why BCM Europe is willing to invest a staggering $815 million 👇 And peeps are selling their shares for nothing 🤷🏻‍♂️
0 · Reply
Bearbull_Baggins
Bearbull_Baggins Feb. 4 at 12:28 AM
$OSRH Just one spoke of this hub we call OSR Holdings
1 · Reply
KeepItRealistic
KeepItRealistic Feb. 3 at 7:25 PM
$OSRH I can hold a couple months for $10+ No brainer 👇
2 · Reply
KeepItRealistic
KeepItRealistic Feb. 3 at 6:48 PM
$OSRH news expected 👇 “As a result of this improved regulatory visibility, Woori IO has recently begun receiving proactive inbound interest from global device distributors, including potential partners prepared to act as importers and local agencies across key international markets. The company aims to announce formal distribution engagements in due course.”
0 · Reply
GemstoneTrades
GemstoneTrades Feb. 3 at 6:28 PM
$OSRH Based on the heavy concentration of news we've seen in the last few weeks, there is a clear "news cycle" pattern forming. The next piece of news will likely drop within the next 7 to 14 days (roughly between February 10th and February 17th, 2026). Here is why that specific window is the most probable: If you look at their recent PR history, they have been releasing a major update roughly every 5 to 10 days: Jan 22: FDA Clarification news. Jan 27: Woori IO Acquisition closing. Feb 2: CEO Statement to Shareholders. Next Window: Mid-February.
0 · Reply
TySpy
TySpy Feb. 3 at 3:31 PM
$OSRH Q elevator music while we wait 🤣
1 · Reply
KeepItRealistic
KeepItRealistic Feb. 3 at 2:47 PM
$OSRH RS fears debunked 👇 See you over $1
0 · Reply
KeepItRealistic
KeepItRealistic Feb. 3 at 1:54 PM
$OSRH smart money sucking up the dumb sellers !
0 · Reply
Genesys01
Genesys01 Feb. 3 at 12:42 PM
$OSRH This 0.56 stock value brings me really in trouble: I have already 200k shares now and my plan was to wait for nearby double digits. And now this low stock price makes me greedy again. Will I stay at 200k or will it be more. I guess I will buy more. OK, decision is done now, next target is 250k.
1 · Reply
Bearbull_Baggins
Bearbull_Baggins Feb. 3 at 1:47 AM
$OSRH And by the way, there are about 70 million samsung smart watch users worldwide. Samsung is aiming for there niche to be targeted towards health. Woori is fully expecting to see hundreds of millions of dollars in value over the next couple years from this partnership. They are not messing around
0 · Reply
Bearbull_Baggins
Bearbull_Baggins Feb. 3 at 1:43 AM
$OSRH A few things those shorting this stock just don't get: 1) Woori IO is a legit, and Samsung chose to partner with them to use their tech for their smart watches and galaxy watches. These don't need FDA approval but as partners they are still going through with clinical trials to acheive FDA approval. The watches will be sold commercially either way. But Samsung obviously sees something in Wooris tech that they can get the only FDA approval and make wearables even more mainstream. 2) 70% of the float is locked up by insiders and private corporations. A large portion of the rest is being gobbled up by regular retail investors, and the remainder will soon be gobbled up new Korean investors. And none of us would be selling shares for cheap. 3) I could go on about their other asset Vaxxim as well but the term sheet will speak for itself. If you a short on a 57 cent stock, the above 2 points should be more than enough to make you check your greed.
0 · Reply
KeepItRealistic
KeepItRealistic Feb. 3 at 1:43 AM
$OSRH here is a recent example of another Nasdaq company getting the extension and doing a PR on it👇 https://www.prnewswire.com/news-releases/scienjoy-holding-corporation-granted-additional-180-day-extension-by-nasdaq-to-regain-compliance-with-minimum-bid-price-rule-302657181.html I expect same type of PR here closer to the expire date in early March. Anyone trying to spread RS fears here is likely a short or an idiot 😝 With an additional 6 month extension and the mega catalysts this company has, they will not need to do an RS as they will be trading well above $10 by then me thinks !!!
0 · Reply
KeepItRealistic
KeepItRealistic Feb. 2 at 11:52 PM
$OSRH (OSR Holdings, Inc.) does not need to have a proxy with reverse stock split (RS) approval secured before the end of the initial 180-day compliance period (March 4, 2026) to qualify for the second 180-day extension under Nasdaq Listing Rule 5810(c)(3)(A). The rule’s requirements for the second compliance period (applicable to Nasdaq Capital Market companies like OSRH) are: - At the end of the first 180-day period, the company must meet all other applicable initial listing standards for the Nasdaq Capital Market except the bid price requirement (e.g., market value of publicly held shares, number of shareholders, etc.), based on the most recent public filings and market data. Read on 👇 Knowledge is your friend
0 · Reply
KingEdward
KingEdward Feb. 2 at 11:03 PM
$OSRH This is a friendly reminder that this is getting ready to pop any day now.
0 · Reply
KeepItRealistic
KeepItRealistic Feb. 2 at 9:59 PM
$OSRH wow ! Nice looking device !
0 · Reply
M1Tanker
M1Tanker Feb. 2 at 9:02 PM
$OSRH adding k pop gifs for excitement
1 · Reply
M1Tanker
M1Tanker Feb. 2 at 9:01 PM
$OSRH down we go
1 · Reply
Genesys01
Genesys01 Feb. 2 at 9:01 PM
$OSRH Look what OSRH has: 1 for Continuous Glucose monitoring 1 for spontaneous Glucose Monitoring CGM without needle, could be used at Samsung watches or Apple watches. Was there something else? Oh, yes - Samsung is already a partner of Woori / OSRH. https://woori-io.imweb.me
0 · Reply
Spiderman1979
Spiderman1979 Feb. 2 at 8:49 PM
$OSRH they are really trying to shake us out!
1 · Reply